AI assistant
SYNTARA LIMITED — Capital/Financing Update 2012
Mar 28, 2012
65830_rns_2012-03-28_f3d15f6c-597e-4091-9e0a-7e923fd7a0c3.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Media Release
29 March 2012
==> picture [153 x 46] intentionally omitted <==
PHARMAXIS ANNOUNCES AGREEMENT FOR EUROPEAN SUPPLY OF BRONCHITOL
Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has finalised a logistics and distribution services agreement for the supply of Bronchitol across Europe.
In anticipation of a second quarter commercial launch of Bronchitol for cystic fibrosis in Europe, Pharmaxis has signed a three year agreement with Arvato Healthcare, a member of the Bertelsmann AG group of companies.
Pharmaxis Chief Executive Officer Dr Alan Robertson said, “This agreement completes the infrastructure required to make Bronchitol available throughout Europe. Arvato provides Pharmaxis with a state‐of‐the‐art healthcare distribution facility centralised in Germany from which Bronchitol is shipped directly to pharmacies and hospitals.
“Launch stock of Bronchitol is in the final stages of manufacture and our Pharmaxis and Quintiles sales teams are introducing Pharmaxis to cystic fibrosis centres in the United Kingdom and Germany. The customer services and logistics are now also in place. We are looking forward to making Bronchitol available to the European cystic fibrosis patients.”
Arvato is an internationally networked outsourcing services provider employing 60,000 people in more than 30 countries. Its integrated business processes and decentralized structure provide a high standard of flexible and efficient service for customers.
#ENDS#
SOURCE: Pharmaxis Ltd, Sydney, Australia CONTACT: Alan Robertson – Chief Executive Officer
Ph: +61 2 9454 7200 or email [email protected]
RELEASED THROUGH:
Australia:
Felicity Moffatt, phone +61 418 677 701 or email [email protected]
About Pharmaxis
Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes, Bronchitol for cystic fibrosis and bronchiectasis and, PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company’s head office and manufacturing facilities are located in Sydney. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.
About Bronchitol
Bronchitol has been developed to help clear mucus (a major source of lung infections), improve lung function and reduce exacerbations in patients with cystic fibrosis.
Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand‐held inhaler. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be safe, effective, and well tolerated in treating patients cystic fibrosis.
About Cystic Fibrosis
In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway‐clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unhealthy lung environment that leads to life‐threatening lung infections.
Forward‐Looking Statements
Forward‐looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward‐looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward‐looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.